D. E. Shaw & Co. Inc. lowered its position in Davita Inc (NYSE:DVA) by 36.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 346,091 shares of the company’s stock after selling 200,974 shares during the period. D. E. Shaw & Co. Inc. owned approximately 0.21% of Davita worth $17,810,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds and other institutional investors have also recently made changes to their positions in DVA. Private Advisor Group LLC bought a new stake in Davita in the third quarter worth about $249,000. Commonwealth Equity Services LLC lifted its stake in Davita by 10.2% in the third quarter. Commonwealth Equity Services LLC now owns 8,168 shares of the company’s stock worth $585,000 after purchasing an additional 757 shares during the last quarter. SG Americas Securities LLC lifted its stake in Davita by 313.5% in the third quarter. SG Americas Securities LLC now owns 25,199 shares of the company’s stock worth $1,805,000 after purchasing an additional 19,105 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. lifted its stake in Davita by 0.3% in the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 478,794 shares of the company’s stock worth $34,296,000 after purchasing an additional 1,603 shares during the last quarter. Finally, MML Investors Services LLC bought a new stake in Davita in the third quarter worth about $408,000. 85.34% of the stock is owned by institutional investors and hedge funds.
Davita stock opened at $55.00 on Friday. The company has a quick ratio of 1.70, a current ratio of 1.72 and a debt-to-equity ratio of 2.09. Davita Inc has a fifty-two week low of $48.25 and a fifty-two week high of $79.11. The company has a market cap of $8.94 billion, a PE ratio of 15.09, a P/E/G ratio of 0.54 and a beta of 1.30.
Several brokerages have issued reports on DVA. Royal Bank of Canada reissued a “hold” rating and issued a $65.00 price objective on shares of Davita in a research note on Wednesday, January 9th. Raymond James raised shares of Davita from a “market perform” rating to an “outperform” rating and set a $70.00 price objective for the company in a research note on Wednesday, November 28th. They noted that the move was a valuation call. Zacks Investment Research raised shares of Davita from a “sell” rating to a “hold” rating in a research note on Thursday, February 14th. SunTrust Banks reissued a “hold” rating on shares of Davita in a research note on Wednesday, February 20th. Finally, ValuEngine downgraded shares of Davita from a “hold” rating to a “sell” rating in a research note on Wednesday, January 2nd. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $66.92.
ILLEGAL ACTIVITY NOTICE: This article was originally published by Ticker Report and is the property of of Ticker Report. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/4239904/d-e-shaw-co-inc-has-17-81-million-position-in-davita-inc-dva.html.
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Featured Story: What is Blockchain?
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.